Measurement of circulating miRNA‐125a exhibits good value in the management of etanercept‐treated psoriatic patients

摘要

Abstract This study aimed to explore the correlation of miR‐125a with risk and severity of psoriasis, and further investigate the potential of miR‐125a for predicting response to etanercept (ETN) treatment in psoriatic patients. Moderate to severe plaque psoriatic patients ( n ?=?126) about to undergo ETN treatment for 6?months were recruited. Their plasma samples were obtained, and Psoriasis Area and Severity Index (PASI) scores and PASI‐75 response rate were assessed at baseline (M0), and at 1 (M1), 3 (M3) and 6?months (M6) of treatment. Referring to PASI‐75 response status at M6, patients were categorized as PASI‐75 responders and PASI‐75 non‐responders. Healthy controls (HC, n ?=120) were also enrolled and their plasma samples were collected. In addition, plasma miR‐125a was determined by quantitative polymerase chain reaction. miR‐125a was decreased in psoriatic patients compared with HC; further, the receiver–operator curve (ROC) exhibited that miR‐125a was of good value in differentiating psoriatic patients from HC with an area under the curve (AUC) of 0.802. In psoriatic patients, miR‐125a was negatively associated with PASI score to some extent. Interestingly, baseline miR‐125a was lower in PASI‐75 responders than PASI‐75 non‐responders; further, ROC showed it predicted PASI‐75 response at M6 to some extent with AUC of 0.672. Multivariate logistic regression also revealed that miR‐125a was an independent predictive factor for worse PASI‐75 response at M6. Furthermore, miR‐125a expression was gradually increased during the treatment in PASI‐75 responders, but unchanged in PASI‐75 non‐responders. Measurement of circulating miR‐125a exhibits good value in the management of ETN‐treated psoriatic patients.